Jin J, Ginde V, Huhn S, Reichert P, Bertsch U, Fenk R, Besemer B, Boquoi A, Schroers R, Von Metzler I, Hänel M, Mann C, Leypoldt L, Heilmeier B, Scheid C, Peters-Regehr T, Blau I, Müller-Tidow C, Luntz S, Holderried T, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel C, Geer T, Riesenberg H, Lutz C, Raab M, Weinhold N, Hoffmann M, Benner A, Findeisen P, Weisel K, Salwender H, Goldschmidt H, Mai E. P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL. haematol [Internet]. 2026Apr.15 [cited 2026Apr.21];111(s2). Available from: https://haematologica.org/article/view/haematol.2026.s2.14035